[Renal carcinoma: point on treatment of brain metastasis].
Prognosis of patients with renal carcinoma has improved since the advent of targeted therapies. These last years, due to the improvement of patients overall survival, the incidence of brain metastasis among renal carcinoma patients has increased. This worsens the prognosis of patients. The present revue aims to do a point on treatment of brain metastasis from renal carcinoma. It will address both locoregional (surgery, radiotherapy and stereotactic radiosurgery) and systemic (targeted therapies) treatments.
Hôpital européen Georges-Pompidou, service de cancérologie médicale, 20, rue Leblanc, 75015 Paris, France. corinne.takouchop@egp.aphp.fr>
Corine
C
Teghom
Philippe
P
Giraud
Philippe
P
Menei
Jacques
J
Medioni
Réza
R
Elaidi
Pierre
P
Combe
Stéphane
S
Oudard
D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D002292:Carcinoma, Renal Cell / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D000068338:Everolimus; D006801:Humans; D007680:Kidney Neoplasms; D058990:Molecular Targeted Therapy / Q000379:methods; D011379:Prognosis; D016634:Radiosurgery / Q000379:methods; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; C401859:temsirolimus; D000068338:Everolimus; D020794:Receptor Protein-Tyrosine Kinases; D020123:Sirolimus